1 / 27

Estimated Number of Adults and Children Newly Infected with HIV, 2008

HIV Vaccines: where are we, where are we going, and how can we get there faster? 16 July 2010 Alan Bernstein, O.C., Ph.D. Executive Director, Global HIV Vaccine Enterprise. Estimated Number of Adults and Children Newly Infected with HIV, 2008. Eastern Europe & Central Asia 110 000

montana
Download Presentation

Estimated Number of Adults and Children Newly Infected with HIV, 2008

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HIV Vaccines: where are we, where are we going, and how can we get there faster? 16 July 2010Alan Bernstein, O.C., Ph.D.Executive Director,Global HIV Vaccine Enterprise

  2. Estimated Number of Adults and Children Newly Infected with HIV, 2008 Eastern Europe & Central Asia 110 000 [100 000 – 130 000] Western & Central Europe 30 000 [23 000 – 35 000] North America 55 000 [36 000 – 61 000] East Asia 75 000 [58 000 – 88 000] Caribbean 20 000 [16 000 – 24 000] Middle East&North Africa 35 000 [24 000 – 46 000] South & South-East Asia 280 000 [240 000 – 320 000] Latin America 170 000 [150 000 – 200 000] Sub-Saharan Africa 1.9 million [1.6 – 2.2 million] Oceania 3900 [2900 – 5100] Total: 2.7 million (2.4 – 3.0 million)

  3. An Unsustainable Economic Situation

  4. Prevention Approaches and Biomedical Interventions Adapted from A. Fauci, NIH, 2009

  5. Adapted from M. Robb, MHRP, 2010

  6. How an HIV Vaccine Might Work

  7. Timeline Between Disease Identification and Vaccine Development rubella yellow fever hep. A measles hepatitis C jap. encephalitis hepatitis B HIV mumps tetanus HPV diphtheria influenza rotavirus tuberculosis tick encephalitis whooping cough chickenpox cytomegalovirus polio Streptococcal meningitis Haemophilus influenza B typhoid malaria 1900 1920 1940 1960 1980 2000 Vaccine available Partially-effective vaccine No vaccine

  8. How do we Develop Vaccines? Efficacy trials Phase 1 and II trials Clinical research Product development and animal testing New vaccine strategies Fundamental research

  9. Hope for an HIV Vaccine RV144 Modified Intention-to-Treat Analysis • First proof of concept: a vaccine is possible • Need to understand how vaccine reduced risk of HIV acquisition • Important implications for future HIV vaccine design and testing Source: Rerks-Ngarm et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-I Infection in Thailand. N Engl Med 2009; 361.

  10. An Important Moment in HIV Vaccine Research

  11. EMBARGOED UNTIL 11:15 a.m. CST Sunday, 18 July

  12. The 2010 Plan: The Framework For A New Era of HIV Vaccine Research • Developed by the Enterprise Council involving the Enterprise Science Committee and five Working Groups • Input of more than 400 researchers, policy-makers, funders and advocates worldwide • An agreement of partners to align their independent strategies to maximize opportunities for cooperation in HIV vaccine research

  13. Transforming the Global HIV Vaccine Research Effort Unified clinical trials agenda Rapid data sharing New minds and new ideas Broaden and increase funding v

  14. Global HIV Vaccine Enterprise: Promoting Scientific Collaboration AIDS Vaccine Asian Network v

  15. Upcoming Enterprise 2010 Plan Activities AIDS 2010, Vienna (18 – 23 July) Satellite Session: The Search for an HIV Vaccine: Where are we, where are we going, and how can we get there faster?” 11:15 – 13:15, Mini Room 6 Press Conference: Entering the Next Phase in HIV Vaccine Research, the Future Course of the Field Monday, 19 July 12:00 – 13:00, Press Room 1 Vaccine Session: HIV Vaccines – Quo Vadis? Tuesday, 20 July 14:30 – 16:00, Session Room 3 Enterprise BoothSection E, booth 476 AIDS Vaccine 2010, Atlanta (28 Sept. – 1 Oct.) Plenary Session: Launch of the Global HIV Vaccine Enterprise 2010 Plan Wednesday, 29 September 14:30 - 16:00

More Related